Stockreport

BRIEF-Ultragenyx proposes to acquire Dimension Therapeutics for $5.50 per share in cash [Reuters]

DIMENSION THERAPEUTICS  (DMTX) 
US:NASDAQ Investor Relations: investors.dimensiontx.com
PDF BRIEF-Ultragenyx proposes to acquire Dimension Therapeutics for $5.50 per share in cash | Reuters Reuters Staff 1 Min Read Sept 18 (Reuters) - Ultragenyx Pharmaceutical [Read more]